首页 | 本学科首页   官方微博 | 高级检索  
检索        

胰岛素胶囊在Beagle犬体内的药动学和药效学研究
引用本文:李亚卓,李薇,张星艳,赫宇霏,魏滋鸿,武卫党,慈小燕,孙磊,江立新,刘昌孝,伊秀林,曾勇.胰岛素胶囊在Beagle犬体内的药动学和药效学研究[J].现代药物与临床,2017,32(11):2077-2081.
作者姓名:李亚卓  李薇  张星艳  赫宇霏  魏滋鸿  武卫党  慈小燕  孙磊  江立新  刘昌孝  伊秀林  曾勇
作者单位:1. 天津药物研究院新药评价有限公司 释药技术与药代动力学国家重点实验室,天津,300301;2. 安徽医科大学 药学院,安徽 合肥,230032;3. 沈阳药科大学,辽宁 沈阳,110016;4. 合肥天麦生物科技发展有限公司,安徽 合肥,230601
基金项目:国家重点研发计划项目(2016YFE0121400);国家科技重大专项重大新药创制项目(2012ZX09304002)
摘    要:目的研究胰岛素胶囊在Beagle犬体内药动学和药效学特征。方法 4只健康Beagle犬sc重组人胰岛素注射液以及po和内窥镜给予胰岛素胶囊,不同时间经静脉采集血浆标本,同步测定血糖水平,采用放射免疫分析法检测血药浓度。结果 4只Beagle犬自身交叉分别sc胰岛素注射液和po胰岛素胶囊或内窥镜给予内容物后,以血浆外源性胰岛素浓度计算得到的主要药动学参数,t_(1/2)分别为(0.986±0.185)、(0.649±0.508)、(0.518±0.187)h;C_(max)分别为(102.0±45.7)、(625.0±360.0)、(453.0±636.0)μU/mL;tmax分别为(0.375±0.224)、(0.750±0.289)、(0.500±0.601)h;AUC_(0-t)分别为(181.0±42.6)、(414.0±246.0)、(423.0±526.0)μU/(mL·h)。胰岛素胶囊po和内窥镜插管给药的相对生物利用度分别为(5.41±2.26)%、(8.31±9.94)%。po和内窥镜这两种途径的胰岛素胶囊在0.5~1.0 h浓度达到最大,然后在血液中的外源性胰岛素浓度逐渐降低,直至检测不到,波动范围较大;t_(1/2)基本为0.5 h左右,作用时间较短;血糖值降低的维持时间较短,回升速度快,且血糖值的波动较大。结论通过直接po和内窥镜给予胰岛素胶囊内容物,与sc短效胰岛素的结果相比,尽管口服胰岛素胶囊在Beagle犬体内吸收和消除均比较快,动物的个体差异影响较明显;但是仍然具有降糖的作用。

关 键 词:胰岛素胶囊  重组人胰岛素注射液  Beagle犬  药动学  药效学  生物利用度
收稿时间:2017/6/6 0:00:00

Pharmacokinetics and pharmacodynamics of Insulin Capsules in Beagle dogs
LI Ya-zhuo,LI Wei,ZHANG Xing-yan,HE Yu-feng,WEI Zi-hong,WU Wei-dang,CI Xiao-yan,SUN Lei,JIANG Li-xin,LIU Chang-xiao,YI Xiu-lin and ZENG Yong.Pharmacokinetics and pharmacodynamics of Insulin Capsules in Beagle dogs[J].Drugs & Clinic,2017,32(11):2077-2081.
Authors:LI Ya-zhuo  LI Wei  ZHANG Xing-yan  HE Yu-feng  WEI Zi-hong  WU Wei-dang  CI Xiao-yan  SUN Lei  JIANG Li-xin  LIU Chang-xiao  YI Xiu-lin and ZENG Yong
Institution:State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research New Drug Evaluation Company Ltd, Tianjin 300301, China,State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research New Drug Evaluation Company Ltd, Tianjin 300301, China,School of Pharmacy, Anhui Medical University, Hefei 230032, China,Shenyang Pharmecutical University, Shenyang 110016, China,State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research New Drug Evaluation Company Ltd, Tianjin 300301, China,State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research New Drug Evaluation Company Ltd, Tianjin 300301, China,State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research New Drug Evaluation Company Ltd, Tianjin 300301, China,Tianmai Biological Technology Development Company Limited, Hefei 230601, China,Tianmai Biological Technology Development Company Limited, Hefei 230601, China,State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research New Drug Evaluation Company Ltd, Tianjin 300301, China,State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research New Drug Evaluation Company Ltd, Tianjin 300301, China and State Key Laboratory of Drug Delivery Technology and Pharmacokinetics, Tianjin Institute of Pharmaceutical Research New Drug Evaluation Company Ltd, Tianjin 300301, China
Abstract:Objective To study the pharmacokinetic and pharmacodynamic characteristics of Insulin Capsules in Beagle dogs. Methods Four healthy Beagle dogs were given subcutaneous injection of Recombinant Human Insulin Injection and oral and endoscopic administration of Insulin Capsules. Plasma samples were collected at different time points and blood glucose levels were measured synchronously. Blood concentration of serum was determined by radioimmunoassay (RIA) method. Results After 4 Beagle dogs themselves crossed were given insulin preparations, t1/2 were (0.986 ± 0.185), (0.649 ± 0.508), and (0.518 ± 0.187) h, the Cmax was (102.0 ± 45.7), (625.0 ±360.0 ), and (453.0 ± 636.0) μU/mL, tmax were (0.375 ± 0.224), (0.750 ± 0.289), and (0.500 ± 0.601) h, AUC0-t was (181.0 ± 42.6), (414.0 ± 246.0), and (423.0 ± 526.0) μU/(mL·h), F of oral and endoscopic administration of Insulin Capsules were (5.41 ± 2.26)% and (8.31 ± 9.94)%, respectively. Insulin concentration of oral and endoscopic administration of Insulin Capsules reached the maximum during 0.5 — 1 h, then the exogenous insulin concentration in the blood gradually decreased until undetectable and with larger range. T1/2 was about 0.5 h with short response time. The maintenance time of blood glucose value was shorter, the recovery rate was faster, and the fluctuation of blood sugar value was larger. Conclusion Compared with subcutaneous injection of Recombinant Human Insulin Injection, Absorption and elimination of insulin in Beagle dogs by oral and endoscopic administration of Insulin Capsules are faster. and the individual difference of animals are more obvious, but there are still has hypoglycemic effect.
Keywords:Recombinant Human Insulin Injection  Insulin Capsules  Beagle dogs  pharmacokinetics  pharmacodynamics  bioavailability
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号